Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Cannabidiol in cancer survivors suffering from chemotherapy-induced peripheral neuropathy: Interplay between immunological parameters and gut microbiome

FY 2022-23

Summary
Cancer patients treated with chemotherapy often suffer from severe burning pain and tingling sensations in their hands and feet, even after being cured from cancer. This condition, called “chemotherapy-induced peripheral neuropathy” (CIPN), results from chemotherapy-caused damage to peripheral nerves and inflammation. It affects up to 80% of cancer survivors, and causes impairments in the activities of daily living and poor quality of life. Presently, CIPN is being treated with pain medications like Tylenol, morphine and anti-depressants, which are not very effective, and carry significant side effects. Thus, there is an urgent need to find safer and more effective treatments for CIPN. Cannabidiol (CBD), one of the main active ingredients of cannabis could be one of these treatments. This project will investigate whether CBD can be used to relieve CIPN in 40 cancer survivors recruited from the McGill University Health Center and the Jewish General Hospital in Montreal, Quebec. Information on age, sex, gender, cancer type, drug type, pain scores and quality of life will be recorded before and after CBD treatment. Blood and fecal samples will be also collected and analysed. Through state-of-the-art technologies, the effects of CBD on pain, immune status, inflammation and intestinal bacteria will be investigated. The results of this project will inform whether CBD may be used as a novel, more effective and safer treatment to help cancer survivors who are suffering from CIPN.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486045
Name
Vigano MariaLuisa
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Cannabidiol in cancer survivors suffering from chemotherapy-induced peripheral neuropathy: Interplay between immunological parameters and gut microbiome
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Care; Cancer Survivors; Cannabinoids; Immune System; Inflammation; Microbiome; Neuropathies; Pain; Quality Of Life
Abstract
Cancer patients treated with chemotherapy often suffer from severe burning pain and tingling sensations in their hands and feet, even after being cured from cancer. This condition, called “chemotherapy-induced peripheral neuropathy” (CIPN), results from chemotherapy-caused damage to peripheral nerves and inflammation. It affects up to 80% of cancer survivors, and causes impairments in the activities of daily living and poor quality of life. Presently, CIPN is being treated with pain medications like Tylenol, morphine and anti-depressants, which are not very effective, and carry significant side effects. Thus, there is an urgent need to find safer and more effective treatments for CIPN. Cannabidiol (CBD), one of the main active ingredients of cannabis could be one of these treatments. This project will investigate whether CBD can be used to relieve CIPN in 40 cancer survivors recruited from the McGill University Health Center and the Jewish General Hospital in Montreal, Quebec. Information on age, sex, gender, cancer type, drug type, pain scores and quality of life will be recorded before and after CBD treatment. Blood and fecal samples will be also collected and analysed. Through state-of-the-art technologies, the effects of CBD on pain, immune status, inflammation and intestinal bacteria will be investigated. The results of this project will inform whether CBD may be used as a novel, more effective and safer treatment to help cancer survivors who are suffering from CIPN.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Vigano, MariaLuisa
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~